Clinical and Dermoscopic Evaluation of the Safety and Efficacy of Oral baricitinib (JAK Inhibitor) in Treatment of Localized Vitiligo Either Alone or with Topical Tacrolimus
(2025). Clinical and Dermoscopic Evaluation of the Safety and Efficacy of Oral baricitinib (JAK Inhibitor) in Treatment of Localized Vitiligo Either Alone or with Topical Tacrolimus. EKB Journal Management System, 98(1), 135-139. doi: 10.21608/ejhm.2025.402419
. "Clinical and Dermoscopic Evaluation of the Safety and Efficacy of Oral baricitinib (JAK Inhibitor) in Treatment of Localized Vitiligo Either Alone or with Topical Tacrolimus". EKB Journal Management System, 98, 1, 2025, 135-139. doi: 10.21608/ejhm.2025.402419
(2025). 'Clinical and Dermoscopic Evaluation of the Safety and Efficacy of Oral baricitinib (JAK Inhibitor) in Treatment of Localized Vitiligo Either Alone or with Topical Tacrolimus', EKB Journal Management System, 98(1), pp. 135-139. doi: 10.21608/ejhm.2025.402419
Clinical and Dermoscopic Evaluation of the Safety and Efficacy of Oral baricitinib (JAK Inhibitor) in Treatment of Localized Vitiligo Either Alone or with Topical Tacrolimus. EKB Journal Management System, 2025; 98(1): 135-139. doi: 10.21608/ejhm.2025.402419